Immunologic Research

, 12:258 | Cite as

Membrane defence against complement lysis: The structure and biological properties of CD59

  • Alexandra Davies
  • Peter J. Lachmann
The Year in Complement

Abstract

The complement system is an important branch of the innate immune response, constituting a first line of defence against invading microorganisms which activate complement via both antibody-dependent and-independent mechanisms. Activation of complement leads to (a) a direct attack upon the activating cell surface by assembly of the pore-forming membrane attack complex (MAC), and (b) the generation of inflammatory mediators which target and recruit other branches of the immune system. However, uncontrolled complement activation can lead to widespread tissue damage in the host, since certain of the activation products, notably the fragment C3b and the C5b-7 complex, can bind nonspecifically to any nearby cell membranes. Therefore it is important that complement activation is tightly regulated. Our own cells express a number of membrane-bound control proteins which limit complement activation at the cell surface and prevent accidental complement-mediated damage. These include decay-accelerating factor, complement receptor 1 and membrane cofactor protein, all of which are active at the level of C3/C5 convertase formation. Until recently, cell surface control of MAC assembly had been attributed to a single 65-kD membrane protein called homologous restriction factor (alternatively named C8-binding protein and MAC-inhibiting protein). However a second MAC-inhibiting protein has since been discovered and it is now clear that this protein plays a major role in the control of membrane attack. This review charts the rapid progress made in elucidating the protein and gene structure, and the mechanism of action of this most recently discovered complement inhibitor, CD59.

Key Words

CD59 Homologous restriction Complement control proteins Membrane attack complex 

References

  1. 1.
    Muir R, Browning CH: On chemical combination and toxic action as exemplified in haemolytic sera. Proc R Soc Lond [Biol] 1904;74:298–309.Google Scholar
  2. 2.
    Lachmann PJ, Bowyer DE, Nicol P, Dawson RMC, Munn EA: Studies on the terminal stages of complement lysis. Immunology 1974;24: 135–145.Google Scholar
  3. 3.
    Okada H, Tanaka H: Species-specific inhibition by glycophorin of complement activation via the alternative pathway. Mol Immunol 1983;20:1233–1236.PubMedGoogle Scholar
  4. 4.
    Brauch H, Roelcke D, Rother U: Glycophorin A inhibits lysis by the complement membrane attack phase. Immunobiology 1983;165: 115–120.PubMedGoogle Scholar
  5. 5.
    Lublin DM: Glycosyl-phosphatidyl anchoring of membrane proteins. Curr Topics Microbiol Immunol 1992;178:141–162.Google Scholar
  6. 6.
    Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF: Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982;129:184–189.PubMedGoogle Scholar
  7. 7.
    Davitz MA, Low GM, Nussenzweig V: Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). J Exp Med 1986;163:1150–1161.PubMedGoogle Scholar
  8. 8.
    Zalman LS, Wood LM, Müller-Eberhard HJ: Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 1986;83:6975–6979.PubMedGoogle Scholar
  9. 9.
    Schönermark S, Rauterberg EW, Shin ML, Loke S, Roelcke D, Hansch GM: Homologous species restriction in lysis of human erythrocytes: A membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986; 136:1772–1776.PubMedGoogle Scholar
  10. 10.
    Watts MJ, Patel AK, Morgan BP: C9-binding protein: Purification, characterisation and incorporation into lipid vesicles (abstract). Complement 1987;4:236.Google Scholar
  11. 11.
    Hansch GM, Weller PF, Nicholson-Weller A: Release of C8-binding protein (C8bp) from the cell membrane by phosphatidylinositol-specific phospholipase C. Blood 1988; 72:1089–1092.PubMedGoogle Scholar
  12. 12.
    Sugita Y, Nakano Y, Tomita M: Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 1988;104:633–637.PubMedGoogle Scholar
  13. 13.
    Sugita Y, Tobe T, Oda E, Tomita M, Ysukawa K, Yamaji N, Takemoto T, Furuichi K, Takayama M, Yano S: Molecular cloning and characterisation of MACIF, an inhibitor of membrane channel formation of complement. J Biochem 1989;106: 555–557.PubMedGoogle Scholar
  14. 14.
    Okada N, Harada R, Fujita T, Okada H: Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J Immunol 1989;143: 2262–2266.PubMedGoogle Scholar
  15. 15.
    Holguin MH, Frederick LR, Bernshaw NJ, Wilcox LA, Parker CJ: Isolation and characterisation of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal haemoglobinuria. J Clin Invest 1989;84:7–17.PubMedGoogle Scholar
  16. 16.
    Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ: Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990;71:1–9.PubMedGoogle Scholar
  17. 17.
    Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H: CD59, an LY6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989;170:637–654.PubMedGoogle Scholar
  18. 18.
    Stefanova I, Hilgert I, Kristofova R, Brown R, Low MG, Horejsi V: Characterisation of a broadly expressed human leucocyte surface antigen MEM 43 anchored in the membrane through glycosylphosphatidylinositol. Mol Immunol 1989; 26:153–161.PubMedGoogle Scholar
  19. 19.
    Groux H, Huet S, Aubrit F, Tran HC, Boumsell L, Bernard A: A 19kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. J Immunol 1989; 142:3013–3020.PubMedGoogle Scholar
  20. 20.
    Whitlow MB, Iida K, Stefanova I, Bernard A, Nussenzweig V: H19, a surface membrane molecule involved in T cell activation, inhibits channel formation by human complement. Cell Immunol 1992;126: 176–184.Google Scholar
  21. 21.
    Fletcher A, Bryant JA, Gardner B, Judson PA, Spring FA, Parson SF, Mallinson G, Anstee DJ: New monoclonal antibodies in CD59: Use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology 1992;75:507–512.PubMedGoogle Scholar
  22. 22.
    Mcllhinney RAJ, Patel S: Purification of a human plasma membrane glycoprotein from human red blood cells by affinity chromatography using a monoclonal antibody. J Biol Chem 1985;260:489–494.Google Scholar
  23. 23.
    Okada H, Nagami Y, Takahashi K, Okada N, Hideshima T, Takizawa H, Kondo J: Z0kDa homologous restriction factor of complement resembles T cell activating protein. Biochem Biophys Res Commun 1989;162:1553–1559.PubMedGoogle Scholar
  24. 24.
    Philbrick WM, Palfree RGE, Maher SE, Bridgett MM, Sirlin S, Bothwell ALM: The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon indicibility. Eur J Immunol 1990;20:87–92.PubMedGoogle Scholar
  25. 25.
    Sawada R, Ohashi K, Anaguchi H, Okazaki H, Hattori M, Minato N, Naruto M: Isolation and expression of the full-length cDNA encoding CD59 antigen of human lymphocytes. DNA Cell Biol 1990;9:213–220.PubMedCrossRefGoogle Scholar
  26. 26.
    Fletcher CM, Harrison RA, Lachman PJ, Neuhaus D: Sequence-specific1H-NMR assignments and folding topology of human CD59. Protein Science, in press.Google Scholar
  27. 27.
    Ninomiya H, Stewart BH, Rollins SA, Zhao J, Bothwell ALM, Sims PJ: Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement inhibitory activity. J Biol Chem 1992;267: 8404–8410.PubMedGoogle Scholar
  28. 28.
    Harada R, Okada N, Fujita T, Okada H: Purification of IF5 antigen that prevents complement attack on homologous cell membranes. J Immunol 1990;144:1823–1828.PubMedGoogle Scholar
  29. 29.
    Noda K, Nakano Y, Tobe T, Choi-Miura N, Tomita M, Endo M, Kobata A: Characterisation of a glycosyl-phosphatidylinositol anchor and an N-glycosidic oligosaccharide chain of MACIF (CD59) (abstract). Complement Inflamm 1991;8:199.Google Scholar
  30. 30.
    Sayama K, Shiraishi S, Shirakata Y, Kobayashi Y, Okada N, Okada H, Miki Y: Characterisation of homologous restriction factor (HRF20) in human skin and leucocytes. clin Exp Immunol 1992;82:355–358.Google Scholar
  31. 31.
    Walsh LA, Tone M, Waldmann H: Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement. Eur J Immunol 1991;21:847–850.PubMedGoogle Scholar
  32. 32.
    Rooney IA, Morgan BP: Characterisation of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 1992;76:541–547.PubMedGoogle Scholar
  33. 33.
    Brooimans RA, Van der Ark AAJ, Tomita M, Van Es LA, Daha MR: CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis. Eur J Immunol 1992; 22:791–797.PubMedGoogle Scholar
  34. 34.
    Takizawa H, Takahashi K, Murakami T, Okada N, Okada H: Species-specific restriction of complement by HRF20 (CD59) generated by cDNA transfection. Eur J Immunol 1992;22:1943–1946.PubMedGoogle Scholar
  35. 35.
    Toutant JP, Roberts WL, Murray NR, Rosenberry TL: Conversion of human erythrocyte acetylcholinesterase from an amphiphilic to a hydrophilic form by phosphatidylinositol-specific phospholipase C and phospholipase D. Eur J Biochem 1989;180:503–508.PubMedGoogle Scholar
  36. 36.
    Walter EI, Roberts WL, Rosenbery TL, Ratnoff WD, Medof ME: Structural basis for variations in the sensitivity of human decay-accelerating factor to phosphatidylinositol-specific phospholipase C cleavage. J Immunol 1990;144:1030–1036.PubMedGoogle Scholar
  37. 37.
    Ratnoff WD, Knez JJ, Prince GM, Okada H, Lachmann PJ, Medof ME: Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin Exp Immunol 1992;87: 415–421.PubMedGoogle Scholar
  38. 38.
    Tomita M, Tobe T, Choi-Miura N, Nakano Y, Kusano M, Oda E: Structural analysis of MACIF (CD59) (abstract). Complement Inflamm 1991;8:233.Google Scholar
  39. 39.
    Tone M, Walsh LA, Waldmann H: Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. J Mol Biol 1992;227:971–976.PubMedGoogle Scholar
  40. 40.
    Petranka JG, Fleenor DE, Sykes K, Kaufman RE, Rosse WF: Structure of the CD59-enoding gene: Further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci USA 1992;89: 7876–7879.PubMedGoogle Scholar
  41. 41.
    Forsberg UH, Bazil V, Stefanova I, Schroder J: Gene for human CD59 (likely Ly-6 homologue) is located on the short arm of chromosome 11. Immunogenetics 1989;30:188–193.PubMedGoogle Scholar
  42. 42.
    Bickmore WA, Longbottom D, Oghene K, Fletcher JM, Van Heyningen V: Colocalisation of the human CD59 gene to 11p13 with the MIC11 cell surface antigen. Genomics, in press.Google Scholar
  43. 43.
    Farries TC, Atkinson JP: Evolution of the complement system. Immunol Today 1991;12:295–300.PubMedGoogle Scholar
  44. 44.
    Shevach EM, Korty PE: Ly-6: A multigene family in search of a function. Immunol Today 1989;10:195–200.PubMedGoogle Scholar
  45. 45.
    McKenzie IFC, Cherry M, Snell GD: Ly-6.2: A new lymphocyte specificity of peripheral T cells. Immunogenetics 1977;5:25–32.Google Scholar
  46. 46.
    Halloran PF, Dutton D, Chance H, Cohen Z: An Ly-like specificity with extensive non-lymphoid expression. Immunogenetics 1978;7:185–200.Google Scholar
  47. 47.
    Hein WR, Beya MF: Evidence that the B5 molecule on sheep lymphocytes is a homologue of mouse Ly 6 and human CD59. Immunology 1989;68:580–582.PubMedGoogle Scholar
  48. 48.
    Van den Berg CW, Harrison RA, Morgan BP: The sheep analogue of human CD59: Purification and characterization of its complement inhibitory activity. Immunology 1993;78:349–357.PubMedGoogle Scholar
  49. 49.
    Hughes TR, Piddlesden SJ, Williams JD, Harrison RA, Morgan BP: Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the memrane attack complex of rat complement. Biochem J 1992;284: 169–176.PubMedGoogle Scholar
  50. 50.
    LeClair KP, Rabin M, Nesbitt MN, Pravtcheva D, Ruddle FH, Palfree RGE, Bothwell A: Murine Ly-6 multigene family is located on chromosome 15. Proc Natl Acad Sci USA 1987;84:1638–1642.PubMedGoogle Scholar
  51. 51.
    Meruelo D, Rosamando A, Scandalis S, D'Eustachio P, Fournier REK, Roop DR, Saxe D, Blatt C, Nesbitt MN: Assignment of the Ly-6-Ril-1-Sis-H-30-Pol5/Xmmv-72-Ins-3-Krt-1-Int-1-Gdc-1 region to mouse chromosome 15. Immunogenetics 1987; 25:361–362.PubMedGoogle Scholar
  52. 52.
    Huppi K, Duncan R, Potte M: Myc-1 is centromeric to the linkage group Ly-6-Sis-Gdc-1 on mouse chromosome 15. Immunogenetics 1988;27:215–219.PubMedGoogle Scholar
  53. 53.
    Hanson IM, Seawright A, van Heyningen V: BDNF maps to 11p13. Genomics 1992;13:1331–1333.PubMedGoogle Scholar
  54. 54.
    Siracusa LD, Abbot CM: Mouse chromosome 2. Mamm Genome 1992;3:S20-S43.PubMedGoogle Scholar
  55. 55.
    Williams AF, Tse AGD, Gagnon J: Squid glycoproteins with structural similarities to Thy-1 and Ly-6 antigens. Immunogenetics 1988;27: 265–272.PubMedGoogle Scholar
  56. 56.
    Rolden AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F: Cloning and expression of the receptor for human plasminogen activator, a central molecule in cell surface plasmin-dependent proteolysis. EMBO J 1990;9:467–474.Google Scholar
  57. 57.
    Albrecht JC, Nicholas J Cameron KR, Newman C, Fleckenstein B, Honess RW: Herpesvirus saimin has a gene specifying the homologue of the cellular membrane glycoprotein CD59. Virology 1992;190:527–530.PubMedGoogle Scholar
  58. 58.
    Sims PJ, Rolins SA, Wiedmer T: Regalatory control of complement on blood platelets. J Biol Chem 1989;264:19228–19235.PubMedGoogle Scholar
  59. 59.
    Morgan BP: Isolation and characterisation of the complement inhibiting protein CD59 antigen from platelet membranes. Biochem J 1992;282: 409–413.PubMedGoogle Scholar
  60. 60.
    Nose M, Katoh M, Okada N, Kyogoku M, Okada H: Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 1990;70: 145–149.PubMedGoogle Scholar
  61. 61.
    Hamilton KK, Ji Z, Rollins S, Stewart BH, Sims PJ: Regulatory control of the terminal complement proteins at the surface of human endothelial cells: Neutralisation of a C5b-9 inhibitor by antibody to CD59. Blood 1990;76:2572–2577.PubMedGoogle Scholar
  62. 62.
    Meri S, Waldmann H, Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 1991;65:532–537.PubMedGoogle Scholar
  63. 63.
    Rooney IA, Davies A, Griffiths D, Williams JD, Davies M, Meri S, Lachmann PJ, Morgan BP: The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin Exp Immunol 1991;83:251–256.PubMedGoogle Scholar
  64. 64.
    Holmes CH, Simpson KL, Okada H, Okada N, Wainwright SD, Purcell DFJ, Houlihan JM: Complement regulatory proteins at the fetomaternal interface during human placental development: Distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 1992;22: 1579–1585.PubMedGoogle Scholar
  65. 65.
    Rooney IA, Davies A, Morgan BP: Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. Immunology 1992;75:499–506.PubMedGoogle Scholar
  66. 66.
    Weetman AP, Tandon N, Morgan BP: Anti-thyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet 1992;340:633–636.PubMedGoogle Scholar
  67. 67.
    Tandon N, Morgan BP, Weetman AP: Expression and function of membrane attack complex inhibitory preteins on thyroid follicular cells. Immunology 1992;75:372–377.PubMedGoogle Scholar
  68. 68.
    Nakai H, Hirakawa S, Hayakawa N, Amano T, Ota Z: Enhanced expression of complement regulatory proteins on thyroid epithelial cells of Graves' disease. Acta Med Okayama 1992;46:323–330.PubMedGoogle Scholar
  69. 69.
    Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ: Differential expression of the complement regulatory proteins in the human eye (abstract). J Immunol 1993;150: 227A.Google Scholar
  70. 70.
    Kuraya M, Yefenof E, Klein G, Klein E: Expression of complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: Their role in sensitivity to human serum-mediated lysis. Eur J Immunol 1992;22:1871–1876.PubMedGoogle Scholar
  71. 71.
    Piddlesden SJ, Morgan BP: The role of RIP (rat CD59) in the protection of oligodendrocyes against complement-mediated lysis (abstract). Immunobiology 1992;184:446.Google Scholar
  72. 72.
    Yang C, Barnum SR: Expression and regulation of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes (abstract). J Immunol 1993;150:227A.Google Scholar
  73. 73.
    Meri S, Vakeva A, Laari T, Lachmann PJ: Soluble forms of CD59 antigen: Distribution in body fluids and functional activity (abstract). Complement Inflamm 1991;8:193.Google Scholar
  74. 74.
    Rooney IA, Atkinson JP, Krul ES, Schonfeld G, Polakoski K, Saffitz JE, Morgan BP: Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present in extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med 1993; 177:1409–1420.PubMedGoogle Scholar
  75. 75.
    Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ: Erythrocyte membrane inhibitor of reactive lysis: Effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood 1990;75:284–289.PubMedGoogle Scholar
  76. 76.
    Rollins SA, Sims PJ: The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990;144:3478–3483.PubMedGoogle Scholar
  77. 77.
    Ninomiya H, Sims PJ: The human complement regulatory protein CD59 binds to the α-chain of C8 and to the ‘b’ domain of C9. J Biol Chem 1992;267:13675–13680.PubMedGoogle Scholar
  78. 78.
    Stewart JL, Sodetz JM: Analysis of the specific association of the eighth and ninth comonents of human complement: Identification of a direct role for the alpha subunit of C8. Biochemistry 1985;24:4598–4602.PubMedGoogle Scholar
  79. 79.
    Yoden A, Moriyama T, Inoue K, Inai S: The role for the C9b domain in the binding of C9 molecules to EAC1-8 defined by monoclonal antibodies to C9. J Immunol 1988; 140:2317–2321.PubMedGoogle Scholar
  80. 80.
    Schafer S, Amiguct P, Tschopp J: Transmembrane channel formation by C9 and histones (abstract). Complement Inflamm 1987;4:220–221.Google Scholar
  81. 81.
    Morgan BP: The Biochemistry and Pathology of Complement Component C9. PhD thesis University of Wales, 1984.Google Scholar
  82. 82.
    Koski CL, Ramm LE, Hammer CH, Mayer MM, Shin ML: Cytolysis of nucleated cells by complement: Cell death displays multi-hit characteristics. Proc Natl Acad Sci USA 1983; 80:3816–3820.PubMedGoogle Scholar
  83. 83.
    Davies A, Morgan BP: Expression of the GPI-linked complement inhibiting protein CD59 in insect cells using a baculovirus vector. Biochem J 1993;295:889–896.PubMedGoogle Scholar
  84. 84.
    Okada N, Harada R, Fujita T, Okada H: A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1989;1:205–208.PubMedGoogle Scholar
  85. 85.
    Rollins SA, Zhao J, Ninomiya H, Sims PJ: Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991;146:2345–2351.PubMedGoogle Scholar
  86. 86.
    Takizawa H, Takahashi K, Murakami T, Okada N, Okada H: Species-specific restriction of complement by HRF20 (CD59) generated by DNA transfection. Eur J Immunol 1992;22:1943–1946.PubMedGoogle Scholar
  87. 87.
    Zhao J, Rollins SA, Maher SE, Bothwell ALM, Sims PJ: Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J Biol Chem 1991;266: 13418–13422.PubMedGoogle Scholar
  88. 88.
    Wing MG, Zajicek J, Seilly DJ, Compston DAS, Lachmann PJ: Oligodendrocytes lack glycolipid-anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. Immunology 1992;76:140–145.PubMedGoogle Scholar
  89. 89.
    Podack ER, Hengartner H, Lichtenheld MG: A central role for perforin in cytolysis? Ann Rev Immunol 1991;9:129–167.Google Scholar
  90. 90.
    Zalman LS, Wood LM, Muller-Eberhard HJ: Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes. J Exp Med 1987;166: 947–956.PubMedGoogle Scholar
  91. 91.
    Zalman LS, Brothers MA, Muller-Eberhard HJ: Self-protection of cytotoxic lymphocytes: A soluble form of homologous restriction factor in cytoplasmic granules. Immunology 1988;85:4827–4831.Google Scholar
  92. 92.
    Jiang S, Persechini PM, Zychlinsky A, Liu CC, Perussia B, Ding E, Young J: Resistance of cytolytic lymphocytes to perforin-mediated killing. Lack of correlation with complement-associated homelogous species restriction. J Exp Med 1988; 168:2207–2219.PubMedGoogle Scholar
  93. 93.
    Krahenbuhl OP, Peter HH, Tschopp J: Absence of homologous restriction factor does not affect CTL-mediated lysis. Eur J Immunol 1989;19:217–219.PubMedGoogle Scholar
  94. 94.
    Hollander N, Shin ML, Rosse WF, Springer TA: Distinct restriction of complement- and cell-mediated lysis. J Immunol 1989;142:3913–3916.PubMedGoogle Scholar
  95. 95.
    Okada H, Okada N, Hideshima T: HRF20, a membrane inhibitor of complement attack, does not protect cells from the cytotoxic reaction by lymphokine activated killer cells. Biochem Biophys Res Commun 1990;171:717–721.PubMedGoogle Scholar
  96. 96.
    Meri S, Morgan BP, Wing M, Jones J, Davies A, Podack E, Lachmann PJ: Human protectin (CD59), an 18–20 kD homologous complement restriction factor, does not restrict perforin-mediated lysis. J Exp Med 1990;172:367–370.PubMedGoogle Scholar
  97. 97.
    Deckert M, Kubar J, Zoccola D, Bernard-Pomier G, Angelisova P, Horejsi V, Bernard A: CD59 molecule: A second ligand for CD2 in T cell adhesion. Eur J Immunol 1992;22:2943–2947.PubMedGoogle Scholar
  98. 98.
    Hahn WC, Menu E, Bothwell ALM, Sims PJ, Bierer BE: Overlapping but non-identical binding sites on CD2 for CD58 and a second ligand CD59. Science 1992; 256:1805–1807.PubMedGoogle Scholar
  99. 99.
    Arulanandam ARN, Moingeon P, Concino MF, Recny MA, Kato K, Yagita H, Koyasu S, Reinherz EL: A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: Divergence of CD2 ligands during the evolution of humans and mice. J Exp Med 1993;177: 1439–1450.PubMedGoogle Scholar
  100. 100.
    Korty PE, Tedder TF, Shevach EM: Identification of the ligands for the CD59 and LY-6A.2 cell surface antigens. FASEB J 1992;61: 1224.Google Scholar
  101. 101.
    Korty PE, Brando C, Shevach EM: CD59 functions as a signal transduction molecule for human T cell activation. J Immunol 1991;146: 4092–4098.PubMedGoogle Scholar
  102. 102.
    Robinson PJ: Phosphatidylinositol membrane anchors and T-cell activation. Immunol Today 1991;12: 35–41.PubMedGoogle Scholar
  103. 103.
    Robinson PJ, Millrain M, Antoniou J, Simpson E, Meller AL: A glycophospholipid anchor is required for Qa-2-mediated T cell activation. Nature 1989;342:85–87.PubMedGoogle Scholar
  104. 104.
    Su B, Waneck GL, Falvell RA, Bothwell ALM: The glycosyl phosphatidylinositol anchor is critical for Ly-6A/E-mediated T cell activation. J Cell Biol 1991;112:377–384.PubMedGoogle Scholar
  105. 105.
    Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin D: Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinase p56lck and p59fyn1. J Immunol 1992;149:3535–3541.PubMedGoogle Scholar
  106. 106.
    Stefanova I, Horejsi V: Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. J Immunol 1991;147:1587–1592.PubMedGoogle Scholar
  107. 107.
    Stefanova I, Horejsi V, Ansotegni IJ, Knapp W, Stockinger H: GPI-anchored cell-surface molecules complexed to protein tyrosine kinase. Science 1991;254:1016–1019.PubMedGoogle Scholar
  108. 108.
    Thomas PM, Samelson LE: The glycophosphatidylinositol—anchored Thy-I molecule interacts with the p60fyn protein tyrosine kinase in T cells. J Biol Chem 1992;267: 12317–12322.PubMedGoogle Scholar
  109. 109.
    Bohuslav J, Cinek T, Horejsi V: Large, detergent-resistant complexes containing murine antigens Thy-1 and Ly-6 and protein tyrosine kinase p56lck. Eur J Immunol 1993;23:825–831.PubMedGoogle Scholar
  110. 110.
    Cinek T, Horejsi V: The nature of large covalent complexes containing glycosyl-phosphatidylinositolan chored membrane glycoproteins and protein tyrosine kinases. J Immunol 1992;149:2262–2270.PubMedGoogle Scholar
  111. 111.
    Tamai H, Matsuo S, Fukatsu A, Nishikawa K, Sakamoto N, Yoshioka K, Okada N, Okada H: Localisation of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study. Clin Exp Immunol 1991;84:256–262.PubMedGoogle Scholar
  112. 112.
    Lederman MM, Purvis SF, Walter EI, Carey JJ, Medof ME: Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. Proc Natl Acad Sci USA 1989;86:4205–4209.PubMedGoogle Scholar
  113. 113.
    Weiss L, Okada N, Haeffner-Cavaillon N, Hattori T, Faucher C, Kazatchikine MD, Okada H: Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T-lymphocytes of HIV-infected patients. AIDS 1992;6:379–385.PubMedGoogle Scholar
  114. 114.
    Parker CJ: Paroxysmal nocturnal haemoglobinuria and glycosylphosphatidylinositol-anchored proteins that regulate complement. Clin Exp Immunol 1991;86:36–42.PubMedGoogle Scholar
  115. 115.
    Chow FL, Telen MJ, Rosse WF: The acetylcholinesterase defect in PNH: Evidence that the enzyme is absent from the cell membrane. Blood 1985;66:940–945.PubMedGoogle Scholar
  116. 116.
    Selvaraj P, Dustin MI, Silber R, Low MG, Springer TA, Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal haemoglobinuria. J Exp Med 1987;166:1011–1025.PubMedGoogle Scholar
  117. 117.
    Ploug M, Plesner T, Ronne E, Ellis V, Hoyer-Hansen G, Hansen E, Danø K: The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal haemoglobinuria. Blood 1992;79:1447–1455.PubMedGoogle Scholar
  118. 118.
    Pangburn MK, Schreiber RD, Müller-Eberhard HJ: Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal haemoglobinuria. Proc Natl Acad Sci USA 1983;80:5430–5434.PubMedGoogle Scholar
  119. 119.
    Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF: Affected erythrocytes of patients with paroxysmal nocturnal haemoglobinuria are deficient in the complement regulatory protein, decay-accelerating factor. Proc Natl Acad Sci USA 1983;80:5066–5070.PubMedGoogle Scholar
  120. 120.
    Zalman LS, Wood LM, Frank MM, Müller-Eberhard HJ: Deficiency of the homologous restriction factor in paroxysmal nocturnal haemoglobinuria. J Exp Med 1987;165:572–577.PubMedGoogle Scholar
  121. 121.
    Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ: Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal haemoglobinuria. J Clin Invest 1989;84: 1387–1394.PubMedGoogle Scholar
  122. 122.
    Huizinga TW, van der Schoot CE, Jost C, Klaassen R, Kleijer M, von dem Borne AEG, Roos D, Tetteroo PAT: The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature 1988;333: 667–669.PubMedGoogle Scholar
  123. 123.
    Carothers DJ, Hazra SV, Andreson SW, Medof ME: Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal haemoglobinuria leucocytes. J Clin Invest 1990;85:47–54.PubMedGoogle Scholar
  124. 124.
    Ueda E, Nishimura J, Kitani T, Nasu K, Kageyama T, Kim YU, Takeda J, Kinoshita T: Deficient surface expression of glycosylphosphatidylinositol-anchored proteins in B cell lines established from patients with paroxysmal nocturnal hemoglobinuria. Int Immunol 1992;4:1263–1271.PubMedGoogle Scholar
  125. 125.
    Mahoney JF, Urakaze M, Hall S, DeGasperi R, Chang HM, Sugiyama E, Warren CD, Borowitz M, Nicholson-Weller A, Rosse WF, Yeh ETH: Defective glycosylphosphatidylinositol synthesis in paroxysmal nocturnal haemoglobinuria granulocytes. Blood 1992;79: 1400–1403.PubMedGoogle Scholar
  126. 126.
    Hirose S, Ravi L, Prince GM, Rosenfeld MG, Silber R, Andresen SW, Hazra SV, Medof ME: Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal haemoglobinuria cells. Proc Natl Acad Sci USA 1992;89:6025–6029.PubMedGoogle Scholar
  127. 127.
    Armstrong C, Schubert J, Ueda E, Knez J, Gelperin D, Hirose S, Silber R, Hollan S, Schmidt RE, Medof ME: Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbor a common defect of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-I-murine lymphoma mutants. J Biol Chem 1992;267:25347–25351.PubMedGoogle Scholar
  128. 128.
    Rosse WF: Paroxysmal nocturnal hemoglobinuria: The biochemical defects and the clinical syndrome. Blood Rev 1989;3:192–200.PubMedGoogle Scholar
  129. 129.
    Medof ME, Kinoshita T, Silber R, Nussenzweig V: Amelioration of the lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci USA 1985;82: 2980–2984.PubMedGoogle Scholar
  130. 130.
    Lachmann PJ, Thompson RA: Reactive lysis: The complement-mediated lysis of unsensitised cells. II. Theccharacterisation of activated reactor as C56 and the participation of C8 and C9. J Exp Med 1970;131:643–657.PubMedGoogle Scholar
  131. 131.
    Packman CH, Rosenfeld SI, Jenkins DE Jr, Thiem PA, Leddy JP: Complement lysis of human erythtocytes: Differing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9. J Clin Invest 1979;64:428–433.PubMedGoogle Scholar
  132. 132.
    Merry AH, Rawlinson VI, Uchikawa M, Watts MJ, Sim RB: Lack of abnormal sensitivity to complement-mediated lysis in erythrocytes deficient only in decay-accelerating factor. Biochem Soc Trans 1989;17:514.Google Scholar
  133. 133.
    Telen MJ, Green AM: The Inab phenotype: Characterisation of the membrane protein and complement regulatory defect. Blood 1989;74:437–441.PubMedGoogle Scholar
  134. 134.
    Okada N, Harada R, Taguchi R, Okada H: Complete deficiency of 20 kDa homologous restriction factor (HRF20) and restoration with purified HRF20. Biochem Biophys Res Commun 1989;164: 468–473.PubMedGoogle Scholar
  135. 135.
    Ono H, Kuno Y, Tanaka H, Yamashina M, Takami T, Kondo N, Orii T: A case of paroxysmal nocturnal hemoglobinuria without deficiency of decay-accelerating factor on erythrocytes. Blood 1990; 75:1746–1747.Google Scholar
  136. 136.
    Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N, Okada H, Inoue K, Kitani T: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323:1184–1189.PubMedGoogle Scholar
  137. 139.
    Motoyama N, Okada N, Yamashina M, Okada H: Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur J Immunol 1992;22:2669–2670.PubMedGoogle Scholar
  138. 138.
    Fearon DT: Anti-inflammatory and immuno-suppressive effects of recombinant soluble complement receptors. Clin Exp Immunol 1991;86:43–46.PubMedGoogle Scholar
  139. 139.
    Dalmasso AP, Platt JL, Bach FH: Reaction of complement with endothelial cells in a model of xenotransplantation. Clin Exp Immunol 1991;86:31–35.PubMedGoogle Scholar
  140. 140.
    Akami T, Sawada R, Minato N, Naruto M, Yamada A, Imanishi J, Mitsuo M, Nakai I, Okamoto M, Nakajima H, Arakawa K, Oka T: Cytoprotective effect of CD59 antigen on xenotransplantation immunity. Transplant Proc 1992;24: 485–487.PubMedGoogle Scholar
  141. 141.
    White DJG, Oglesby T, Liszewski MK, Tejda I, Hourcade D, Wang MW, Wright L, Wallwork J, Atkinson JP: Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transplant Proc 1992;24:474–476.PubMedGoogle Scholar
  142. 142.
    Cooper DKC: Is xenotransplantation a realistic clinical option? Transplant Proc 1992;24:2393–2396.PubMedGoogle Scholar
  143. 143.
    Cooper NR: Complement evasion strategies of microorganisms. Immunol Today 1991;12:327–331.PubMedGoogle Scholar
  144. 144.
    Fishelson Z: Complement evasion by parasites: Search for ‘Achilles’ heel'. Clin Exp Immunol 1991;86: 47–51.PubMedGoogle Scholar
  145. 145.
    Parizade M, Lachmann PJ, Amon R, Fichelson Z: A protectin (CD59)-like molecule on the surface ofSchistosoma mansoni (abstract). Complement Inflamm 1991;8:205.Google Scholar
  146. 146.
    Drenth J, Low BW, Richardson JS, Wright CS: The toxin-agglutinin fold. A new group of small protein structures organised around a fourdisuifide core. J Biol Chem 1980; 255:2652–2655.PubMedGoogle Scholar
  147. 147.
    Harrison RA: Motif pattern searching reveals similarities between CD59, a complement regulatory protein, and snake venom neurotoxins (abstract M51). Annu Symp Protein Soc, San Diego, 1992.Google Scholar

Copyright information

© Humana Press Inc. 1993

Authors and Affiliations

  • Alexandra Davies
    • 1
  • Peter J. Lachmann
    • 1
  1. 1.Molecular Immunopathology UnitMRC CentreCambridgeUK

Personalised recommendations